Introduction
The awareness that cancer is a genetic disease and the availability of genomic profiles of tumor samples paved the way to 'precision medicine' in oncology (1) .
In the last ten years, major advances in complex genomic technologies have strongly contributed to the mapping of cancer molecular landscape (2) . The need to understand the impact of the major drivers of cancer development and progression on therapeutic intervention has thus become of paramount importance. Functional characterization and target validation has required generation of reliable cellular and animal models to understand the role of genomic alterations on tumor onset and evolution (3) . Functional studies have proven that the tumor is often dependent on oncogenic alterations for its growth and maintenance, providing a strong rationale for the development of therapies targeting cancer driver genes (4) .
On these premises, modeling disease-associated alterations in models that reflect the clinical features of patients is vital to implement precision medicine. provide an informative clinical platform for pharmacogenomic analysis (5) (6) (7) (8) (9) .
Although these studies aim at providing tools to predict anti-cancer drug response, their complete success is limited by several intrinsic characteristics of cell lines, such as limited capacity to recapitulate inter-and intra-tumor heterogeneity and adaptation to growing in artificial conditions. Genomic instability, loss of molecular heterogeneity and lack of the tumor microenvironment represent the three main issues thought to make a 2D cell line model divergent from the original tumor; for these reasons, the clinical relevance of cell line models has been repeatedly questioned (10) . These drawbacks may play against the recapitulation of the evolutionary nature of cancer itself, thus limiting the translation of the in vitro results to the clinical response of the tumor in the patient. In addition, the frequent unavailability of matched germline tissue has often hampered the confident identification of somatic changes.
To obviate these issues and better bridge the bench-to-bedside gap, patientderived tumor xenografts (PDXs, xenopatients) have been developed.
Although these models had already been described in the seventies, they have become popular for assessing genotype-drug correlation response studies in the last decade (11) . Comprehensive genetic and transcriptomic studies have demonstrated that PDXs maintain the majority of genetic alterations and global pathway activity of primary tumors (12, 13) ; importantly, the histological structure and intratumoral clonal heterogeneity are usually also preserved (14, 15) , although recent literature reports the selection of specific copy number alterations during PDX propagation (16) . In colorectal cancer (CRC), seminal studies have already set the stage for pharmacogenomic analyses and association of PDX genotype with targeted therapy response (12, 17) . PDXs have significantly contributed to shedding light on the mechanisms of resistance and on identification of predictive biomarkers of response, but large-scale screening is actually limited by the costs, size and efforts for animal maintenance and manipulation.
New models that can couple both the ease of handling of cell cultures with the preservation of intra-tumor heterogeneity of PDXs have been proposed.
Bruna and colleagues (5) have generated a large biobank of breast cancer PDXs combined with short-term cultures of PDX-derived cells demonstrating that the corresponding cell models could be reliably used to assess drug response and to identify biomarkers of resistance in vitro, as paralleled in vivo. Similar studies have been recently performed also in gastrointestinal and pancreatic cancer (18, 19) , thus confirming the value and applicability of this approach.
In this work, we describe the establishment of a panel of 29 cell lines obtained from a cohort of 29 CRC PDXs and provide a comprehensive genomic analysis of these models. Importantly, we show that the molecular features of xenopatient-derived cell lines closely parallel their matched PDX models. We also show that PDX-derived cell lines constitute a valuable model to interrogate CRC patient molecular vulnerabilities and provide an effective opportunity to reveal patient-specific drug responses and implement precision oncology in CRC.
Materials and Methods

Xenopatient-derived cell line establishment, culture and authentication
For xenopatient generation, fresh surgically resected primary CRC and metastases tissues or biopsies were obtained and collected from consenting patients. All procedures were approved by the Italian Ministry of the Health and the Ethics Committee of the Medical faculty of the University of Rostock, in accordance with generally accepted guidelines for the use of human material. Tumor specimens were cut into small pieces and either frozen (biobanked) or prepared for implantation, as previously described (12, 20) . For tumor implantation, six-week-old female NMRI nu/nu or NOD/SCID mice were used as recipients. All experimental procedures were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Committee on the Ethics of Animal Experiments of the University of Rostock and the Internal Ethical Committee from Animal Experimentation of the Candiolo Cancer Center. Established tumors from xenopatients (1500 mm 3 ) were removed and processed for in vitro culture as described below. PDX tissues were dissociated into single-cell suspension by mechanical dissociation using the Gentle MACS Dissociator (Miltenyi Biotec) and enzymatic degradation of the extracellular matrix using the Human Tumor Dissociation Kit (Miltenyi Biotec) according to the manufacturer's protocol. Cell suspension was centrifuged three times and finally the pellet was resuspended with DMEM/F12 medium containing 10% FBS and 2 mM Lglutamine. The final cell suspension was then filtered through a 70-um cell strainer (Miltenyi Biotec) and cells that were not filtered out were re-suspended in DMEM/F12 medium containing 10% FBS, 2mM L-glutamine, antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin) and 10 μM ROCK inhibitor Y-27632 (Selleck Chemicals Inc) and cultured on collagen-coated plates (Corning) at 37°C in a humidified atmosphere of 5% CO 2 . Medium was changed regularly every three days. Growing cell lines were further passaged and were subjected to three sequential cycles of freezing and thawing to ensure the stability of the cell lines. Growing cell lines were stocked at low passages by cryopreservation. Only in one case (CRC0080), the cell line was established as xenosphere (21) and then adapted to grow in 2D as monolayer. HROC cell lines collection was derived by Michael Linnebacher's laboratory, as previously reported (20) . BT474 and SKBR3 cell lines were purchased by American Type Culture Collection (ATCC) and maintained in DMEM/F12 and DMEM media, respectively, containing 10% FBS, 2mM L-glutamine, antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin) and cultured at 37°C in a humidified atmosphere of 5% CO 2 . XLs were routinely checked for mycoplasma contamination using the Venor GeM Classic Kit (Minerva Biolabs), according to the manufacturer's protocol. XLs, matched PDXs and patient authentication was performed using the Gene Print 10 System (Promega), through Short Tandem Repeats (STR) at 10 different loci (D5S818, D13S317, D7S820, D16S539, D21S11, vWA, TH01, TPOX, CSF1PO and amelogenin). Amplicons from multiplex PCRs were separated by capillary electrophoresis (3730 DNA Analyzer, Applied Biosystems) and analysed using GeneMapperID v.3.7 software (Life Technologies).
DNA extraction and MSI analysis
Genomic DNA samples were extracted from each XL and matched PDX using ReliaPrep gDNA Tissue Miniprep System (Promega). Patient's germline genomic DNA obtained from normal tissue (liver) or PBMCs of each patient was used as reference genome. The MSI status was evaluated by mean of MSI Analysis System kit (Promega), according to manufacturer's protocol. The analysis requires a multiplex amplification of seven markers including five mononucleotide repeat markers (BAT-25, BAT-26, NR-21, NR-24 and MONO-27) and two pentanucleotide repeat markers (Penta C and Penta D). The products were analyzed by capillary electrophoresis in a single injection using ABI 3730 DNA Analyzer capillary electrophoresis system (Applied Biosystems). The results were analyzed using GeneMapper V5.0 software. Sample with instability in one or more markers are defined as MS-instable (MSI-H). Sample with no detectable alterations are MS-stable (MSS). MSI events were evaluated by MSIsensor (22) . Signatures were calculated using a custom Python script.
Exome sequencing and bioinformatic analysis
Exome sequencing was performed in outsource, while data analysis was performed at the Candiolo Cancer Institute. Each triplet of DNA samples (PDX, xeno-cell line, germline) was sent to GATC (Kostanz, DE) that performed library preparation, exome capture, sequencing on Illumina platform and data demultiplexing. Contaminating mouse reads were removed using Xenome (23) . Human sequences were mapped to the hg38 human reference by BWA-mem (24) and PCR duplicates were removed using Picard Mark Duplicates function (broadinstitute.github.io/picard/). Somatic mutational and gene copy number profiles for each XL and matched PDX were obtained subtracting germline profiles as previously described (25) .
Gene copy number analysis
Real-time PCR was performed with 10 ng of DNA per single reaction using GoTaq QPCR Master Mix (Promega) with an ABI PRISM 7900HT apparatus (Applied Biosytems; primers' sequences are available on request). Gene copy numbers were normalized to a control diploid cell line, HCEC.
RNA extraction, analysis and identification of cancer-cell intrinsic subtypes
RNA was extracted using miRNeasy Mini Kit (Qiagen), according to the manufacturer's protocol. The quantification and quality analysis of RNA was performed on a Bioanalyzer 2100 (Agilent), using RNA 6000 nano Kit (Agilent). Total RNA extracted from XLs was processed for RNA-seq analysis with the TruSeq RNA Library Prep Kit v2 (Illumina) following manufacturer's instruction and sequenced on a NextSeq 500 system (Illumina). Each fastq file was aligned using MapSplice (26) . Version hg19 of the genome was used and Gencode v19 as reference transcriptome database and gene quantification was performed with RSEM (27) . Assignments of each xeno-cell line to cancer-cell intrinsic subtypes and consensus molecular subtypes were performed as previously described (28, 29) . Hierarchical clustering of Xenopatient and matching XenoLine samples was performed with maximum cosine distance using the GEDAS software (30) based on genes whose variance in log2 expression signal was greater than 0.5 in both the Xenopatient and the XenoLine datasets and on CRIS geneset.
Drug proliferation assays CRC XLs were seeded at different densities (5-7 x10 3 cells per well) in 100 μl complete growth medium in 96-well plastic culture plates at day 0. The following day, serial dilutions of the indicated drugs were added to the cells in serum-free medium, while medium-only was included as controls. Plates were incubated at 37 °C in 5% CO 2 for 5 or 6 days, after which cell viability was assessed by measuring ATP content through Cell TiterGlo Luminescent Cell Viability assay (Promega). Luminescence was measured by SPARK M10 (Tecan) plate reader. Treated wells were normalized to untreated/DMSO treated wells. For long-term proliferation assays, cells were seeded in 24-wells plates (1x10 4 cells per well) and cultured in the absence and presence of drugs as indicated. Wells were fixed with 3% paraformaldehyde (Santa Cruz) and stained with 1% crystal violet-methanol solution (Sigma-Aldrich) after 2 weeks. All assays were performed independently at least three times.
Cetuximab and trastuzumab were obtained from the Pharmacy at Niguarda Cancer Center in Milan, Italy. Lapatinib was purchased from Selleck Chemicals.
Lentiviral Transduction of HER2 Mutant Colorectal XL-cells
The PIK3CA p.H1047R mutation was inserted into pLenti-PIK3CA-myc-DDK vector (Origene) using site directed mutagenesis with the Quick Change II Site-Directed Mutagenesis kit (Agilent), according to manufacturer's instructions. Primers sequences for PIK3CA site directed mutagenesis were the following: GAAACAAATGAATGATGCACGTCATGGTGGCTGGACAAC (PIK3CA_H1047R_F) and GTTGTCCAGCCACCATGACGTGCATCATTCATTTGTTTC (PIK3CA_H1047R_R). Lentiviral control pLenti-myc-DDK vector was purchased from Origene. Lentiviral control vectors (pRLL empty and FG12 empty), pRLL-KRAS WT, pRLL-KRAS G13D and FG12-BRAF V600E vectors were previously exploited (31, 32) . Lentiviral vector stocks were produced by transient transfection of the transfer plasmids, the packaging plasmids pMDLg/pRRE and pRSV.REV, and the vesicular stomatitis virus (VSV) envelope plasmid pMD2.VSV-G (12, 5, 2.5, and 3 μg, respectively, for 10 cm dishes) in HEK-293T cells. Determination of the viral p24 antigen concentration was done by ALLIANCE HIV-I P24 ELISA 2 PLATE KIT (PerkinElmer Life Science Inc.). Cells were transduced in sixwell plates (3 × 10 5 per well in 2 ml of medium) in the presence of polybrene (8 mg/ml) (Sigma).
Western blotting analysis
Total cellular proteins were extracted by solubilizing the cells in boiling SDS buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, and 1% SDS). Extracts were clarified by centrifugation and protein concentration was determined using BCA Protein Assay Reagent kit (Thermo). Western blot detection was performed with enhanced chemiluminescence system (GE Healthcare) and peroxidase conjugated secondary antibodies (Amersham). The following primary antibodies were used for western blotting (all from Cell Signaling Technology, except where indicated): anti-phospho-HER2 YY1221/1222); anti-HER2 (Santa Cruz); anti-phospho-EGFR (Y1068); anti-EGFR (clone 13G8, Enzo Life Science); anti-vinculin (Millipore); anti-phospho-p44/42 ERK (Thr202/Tyr204); anti-p44/42 ERK; anti-phospho AKT (Ser473); anti-AKT; anti-PTEN; anti-HSP90 (Santa Cruz); anti-GAPDH (Abcam).
In vivo treatment
Established tumors (average volume 400 mm 3 ) were treated with the following regimens, either single-agent or in combination: lapatinib (Carbosynth) 100 mg/kg, daily (vehicle, 0.5% methylcellulose, 0.2% Tween-80); trastuzumab (Roche), 30 mg/kg once weekly (vehicle: physiological saline). Tumor size was evaluated once weekly by caliper measurements, and the approximate volume of the mass was calculated using the formula 4/3 (d/2)2 D/2, where d is the minor tumor axis and D is the major tumor axis. Animal procedures were approved by the Ethical Commission of the Candiolo Cancer Institute and by the Italian Ministry of Health.
Statistical Analysis
Results were expressed as means ± standard error of the mean (SEM) or standard deviation (SD) as indicated in the legend. Statistical significance was evaluated by t test or two-way ANOVA, using GraphPad Prism software. P<0.05 was considered statistically significant.
Results
Establishment of PDX-derived cell lines
We derived primary cell lines from a set of CRC PDX models with the goal of setting up a platform of in vitro CRC preclinical models closely resembling patient's features. The clinico-pathological characteristics of patients from whom the PDXs were initially obtained are listed in Supplementary Table S1 ; the establishment procedure, described in detail in the 'materials and methods' section, is schematically represented in Supplementary Fig. S1 .
Briefly, the PDX tumor is surgically excised and mechanically and enzymatically dissociated, to obtain cells that are subsequently cultured in 2D petri dishes. In this work, a total of 29 primary cell lines have been derived from a collection of 29 PDXs established at the Candiolo Cancer Institute (n= 17) and at Rostock University (n=12) (12, 17, 20) . Among the 29 PDXs, 10 were originated from primary tumors and 19 from liver or peritoneum metastases of 28 CRC patients (two different metastatic lesions -IRCC-5A and IRCC-5B -were obtained from the same patient) ( Fig. 1A and Supplementary Fig. S1 ). To underline the origin of these 2D primary cell lines from xenopatients, we will refer to them as xeno-cell lines (XLs).
XLs, although presenting cell-specific morphological features, displayed a predominant and typical epithelial pattern characterized by islets of compact or round shaped cells growing predominantly as a monolayer or, in one case (HROC147), as cell-clumps in suspension ( Supplementary Fig. S2 ). The epithelial phenotype was confirmed by analysis of expression of specific epithelial markers (e.g. E-cadherin, cytokeratin 8, 18 and 19 and EpCAM) with respect to mesenchymal markers (e.g. vimentin, SNAIL and TWIST1) ( Supplementary Fig. S3 ).
All 29 XLs displayed the ability of long-term propagation (multiple passages)
in vitro and their stability was ensured by at least three sequential freezing/thawing cycles prior to bio-banking. Cells were maintained in culture for at least 8 passages prior to nucleic acid extraction.
Xeno-cell lines recapitulate the genomic landscape of matched patientderived xenografts
To assess whether the CRC molecular subtypes that are commonly ascertained in the clinic were preserved in both the PDXs and the matched 2D XLs, we performed genomic and transcriptomic analyses systematically comparing the two preclinical platforms.
Initially we analyzed microsatellite markers and found that 5 out of 29 (17%) PDXs displayed microsatellite instability (MSI-H), while the remaining were microsatellite stable (MSS). The MSI status was maintained in the matched XLs ( Fig. 1B) (33) .
RNA expression-based correlation analysis between XLs and their originating
PDXs, which had been subject to gene expression analysis in a previous independent study (28) , revealed higher correlation between matched XL-PDX pairs than between unmatched pairs (Kolmogorov-Smirnov, P < 1x10 -16 , Supplementary Fig. S4A ); furthermore, hierarchical clustering always preferentially aggregated each XL with the PDX sample of origin ( Supplementary Fig. S4B ).
Next, parallel exome sequencing analyses of XLs and matched PDXs were performed. Importantly, to identify tumor-specific somatic mutations, germline genomic DNA (gDNA) extracted from normal tissues (liver) or blood (PMBCs) of the patient was used as reference genome. P<.0001) ( Supplementary Fig. S5A ). Overall, somatic mutations detected in PDXs are highly preserved in cell lines ( Supplementary Fig. S5B ). This is consistent with the reported mutation frequency in CRC tissues and cell lines (2, 7, 34) . No MSS model was found to be hypermutated, likely reflecting the lack of mutations in POLE or POLD1, which are known to generate mutations in the absence of MSI-H (2) . Moreover, the INDEL burden was higher in MSI-H rather than MSS models (median value MSI-H = 562.5 vs MSS = 7), as previously reported in TCGA cancers and CRC cell lines (2,34) ( Fig. 1E and Supplementary Fig. S5C ).
MSI-H models
Somatic variants within the coding regions in XLs were highly concordant with the corresponding xenopatient specimens for both MSS and MSI-H models (median value = 0.78 frequency of concordance, range 0.48-0.93) ( Supplementary Fig. S5D ). The allelic frequencies of alterations shared between XLs and corresponding PDXs were significantly correlated (Pearson correlation coefficient r = 0.8233)( Supplementary Fig. S5E ).
Despite the global genetic correlation between the two models, we also detected some divergent mutations identified only in XLs or in PDXs (private mutations). The putative biological significance in cancer of these private mutations identified only in XLs (n=4174) or PDXs (n=1997) was assessed on Cancer Gene Census and data reported from CRC analysis (35, 36 Supplementary Table S2 ).
While the SNVs spectrum was maintained between XLs and matched PDXs, it differed significantly between the MSI-H and MSS cases, with an increased proportion of C>G/G>C transversion (about 5-fold) and a decrease in T>C/A>G transition in the MSS cases (about 1.3-fold, Fig. 1F ). Interestingly, MSI-H models present a SNV spectrum typically associated with defective DNA mismatch repair and found in microsatellite unstable CRCs (37) ( Supplementary Fig. S6 ).
Finally, exome analysis revealed, when considering copy number variation (CNV) profiles, that the copy number profile of each PDX is also maintained in each derived cell line (Pearson correlation 0.82 ≤ r ≤ 0.98). As expected, MSS xenopatients and matched XLs displayed a higher level of segments of loss of heterozygosity (LOH) or copy-number variations than MSI models, which showed a more stable CNV profile ( Fig. 2A) . In MSS cases, the most common deleted chromosomal arms were 8p, 17p (including TP53), and 18q (including SMAD4), and the most common gained regions were chromosome 7, 8q (including MYC), 13, and 20q ( Fig. 2B and 2C) .
CRC pathway alterations are conserved in xeno-cell lines
Integration of genomic results allowed the identification of deregulated signaling pathways; the genes most commonly altered in CRC (2) were all represented in our panel of PDXs and matched cell lines (Fig. 3A) . In particular, recurrent alterations in the DNA mismatch repair (MMR), WNT, MAPK, PI3K/PTEN, TGF- and p53 pathways were identified (Fig. 3A) .
Mutations in MMR genes were found in MSI-H tumors. These alterations involve missense mutations in MSH2, MSH3, MSH6 and POLE/POLD1 genes, as well as MLH1 expression downregulation (Fig. 3A) . Interestingly, 3 MSS cases displayed alterations in MSH3, MSH6 and POLE MMR-associated genes in both xenopatients and matched XLs. These mutations were not reported previously, nor did they fall in regions important for protein activity, suggesting that these genes are not functionally affected by these mutations.
The WNT pathway is frequently altered (90%) in CRC. The most frequent alterations include inactivating mutations in APC as well as activating mutations in CTNNB1 (2) . Other variants affecting this pathway are inactivating mutations targeting regulators of the Wnt pathway, such as TCF7L2, FBXW7, AXIN2 and RNF43 genes.
APC mutants were identified in 14 out 29 cases (48.28%), while other alterations were found in the same pathway in wild-type APC cases, such as a FBXW7 alteration (p.R465H) found in one case, and an AXIN2 downregulation or mutation (p.G495A) in other three cases. Similarly, RNF43
alterations were identified in one MSS APC wild-type cell line and in four out of five microsatellite unstable cases, highlighting the association of these alterations with the MSI-H phenotype, as previously reported (38) . Of interest, multiple alterations affecting this gene co-occurred in two APC wild-type cases.
In addition, a specific translocation of the Wnt-agonistic RSPO3 with PTPRK was found in one BRAF-mutated APC wild-type case, as assessed by RNAseq analysis on XLs and validated by quantitative RT-PCR ( Fig.3B and Supplementary Fig. S7A and S7B) . No RSPO2 gene fusions were identified in our collection of XLs.
We also evaluated the genetic status of TP53 that resulted altered in 79.3% of cases (23/29). In addition, alterations in ATM were found in 10.35% (3/29), one of these co-occurred with a TP53 mutation, while the remaining two cases were TP53 wild-type.
The TGF-β signaling pathway is also frequently deregulated in CRC (2). In our dataset, we identified 2 TGFBR1 mutated cases and four cases carrying TGFBR2 alterations. Consistent with previous findings (39) , all of these models were MSI-H. Moreover, alterations in SMAD4 were identified in 7 cases, while other 4 cases (CRC0781-XL, CRC0691-XL, HROC59 and HROC239) did not express SMAD4, as assessed by RNA-seq analysis ( Fig.   3A and Supplementary Fig. S7C ); lack of SMAD4 expression was ascribed to LOH in three cases (Fig. 2C) (40) . In addition, western blot analysis highlighted the loss of PTEN expression in two xeno cell lines, CRC0394-XL carrying the p.R233* nonsense mutation, and HROC277, in which PTEN expression was consistently decreased at the transcript level due to genetic loss of the PTEN locus ( Fig. 2C, Supplementary Fig. S7C and S7D ).
Alternative ways of activation for PIK3CA pathway include transcriptional upregulation of IGF2 ( Supplementary Fig. S7E ). In our panel of XLs, we identified seven cases (CRC0081-XL, CRC0438-XL, HROC46, HROC278Met, HROC59, HROC239 and HROC285) overexpressing the IGF2 transcript, as assessed by RNA-seq analysis (log2 ratio > 1.5) ( Supplementary Fig. S7E ). Of note, overexpression of IGF2 was not associated to genomic amplification of the IGF2 gene, as previously reported ( Fig. 2C) (2, 41) .
Other identified alterations in the MAPK pathway included an activating mutation (p.K57N) in MAP2K1 (encoding the protein MEK1) observed in one XL and its matched PDX (CRC0740).
Evaluation of genetic alterations in receptors of the ERBB family receptors
unveiled the presence of an EGFR extracellular mutation (p.G465E) in a PIK3CA-mutated case (CRC0104-XL). Of interest, this EGFR mutation was previously found to be associated with acquired resistance to anti-EGFR therapies (42, 43) . Indeed, its corresponding xenopatient was established from a liver metastasis of a patient who had received cetuximab treatment within six months prior to resection (17) .
Another clinically actionable ERBB family member frequently altered in cancer is ERBB2 (also known as HER2); ERBB2 gene amplification was identified in two MSS wild-type RAS/BRAF cases (CRC0080-XL and CRC0186-XL) ( Fig.   2C and Supplementary Fig. S8A ). Interestingly, CRC0186-XL showed a remarkable increase in ERBB2 gene copy number (n=33.2), while CRC080-XL displayed a less pronounced increase (n=6.1), comparable to that present in the breast cancer cell lines BT474 and SKBR3 (n=6.5 and n=5.6, respectively) ( Supplementary Fig. S8B ). In these cell lines, ERBB2 gene copy number gain led to protein overexpression ( Supplementary Fig. S8C ).
Moreover, CRC0080-XL carried also an ERBB2 activating mutation (p.L866M) affecting the intracellular kinase domain of the receptor (44) (Fig. 3A) .
Mutations in the extracellular region of the ERBB2 receptor (p.S310F and p.L465V) were identified in two additional xenopatients and matched cell lines (HROC87 and HROC112Met, respectively). Of note, ERBB2 p.S310F was copresent in a BRAF p.V600E mutated case. Similarly, in another BRAF mutated case (HROC131), we identified co-occurrence of the ERBB3 p.V104M variant (Fig. 3A) .
Finally, expression analysis revealed that molecular subtypes found in XLs correlated with transcriptional classes identified by the recently described CRC intrinsic subtype (CRIS) analysis (28) ( Fig. 3A and C) . Indeed, hierarchical clustering based on CRIS-classifier genes, as already seen for the whole transcriptome, preferentially clustered XLs with the PDXs of origin ( Supplementary Fig. S4 ). In total, 26 out of 29 XLs were significantly assigned to a specific CRIS class ( Supplementary Table S3 ). In particular, MSI-H and KRAS/BRAF mutant cells were enriched in CRIS-A, while CRIS-C included KRAS/BRAF-WT lines. In addition, 2 cell lines that displayed TGF-β pathway alteration clustered in CRIS-B and IGF-2 overexpressing cells were included in CRIS-D group ( Fig. 3 and Supplementary Table S3 ). A similar distribution in genetic alterations was also found for the consensus molecular subtypes LGR5 pathwaycaptured by the two classifiers. (Fig.   3C ).
Sensitivity to EGFR blockade is maintained in xeno-derived cell lines
Anti-EGFR monoclonal antibodies are approved to treat metastatic CRC and achieve a 10% objective response rate in unselected patients treated with antibody monotherapy (45) . Clinical benefit to EGFR blockade increases up to 25% of cases when tumors are stratified for wild-type KRAS, NRAS and BRAF (45) . To assess whether XLs could recapitulate this genotype-drug response, and therefore could be exploited as a reliable platform for drug testing, we checked the entire cell platform for cetuximab sensitivity.
Based on the level of response to cetuximab, the cell collection was classified in 3 different groups: sensitive (n=2), intermediate (n=5) and resistant (n=22) ( Fig. 4) . As observed in the clinic, KRAS, BRAF or NRAS mutations, as well as other genetic alterations (i.e. MAP2K1 p.K57N and EGFR p.G465E) associated with resistance to EGFR blockade in CRC cells ( Fig. 4 ) (17, 25, 42, 46) . Similarly, ERBB2-amplified CRC0186-XL was refractory to cetuximab treatment, confirming previous findings obtained by pre-clinical and clinical data from the same individual patient (12, 17) . Conversely, the other ERBB2-amplified and mutated CRC0080-XL cell line displayed higher sensitivity to cetuximab treatment.
Integration of multi-layer data revealed also a positive correlation with the transcriptional classes obtained from the cancer cell intrinsic classifier ( Supplementary Table S3 ). As previously reported, CRIS-A resulted enriched in both MSI-H and KRAS/BRAF mutated cases (IRCC-1-XL, HROC50, HROC277, HROC147, CRC0438-XL and CRC0781-XL) with marked resistance to cetuximab treatment (Fig. 3C) , and CRIS-C depleted for KRAS mutant cells (IRCC-5A-XL, IRCC-5B-XL, CRC0078-XL, CRC0080-XL and CRC394-XL), showing sensitivity to anti-EGFR treatment. Confirming previous evidences (28, 47) , both CRIS-C and CMS2 transcriptional classes are enriched for cetuximab responsive models ( Supplementary Table S4 ).
Expression analysis identifies therapeutic targets in xeno-derived cell lines
RNA-seq data analysis unveiled potentially actionable targets in the XL platform. Since receptor tyrosine kinases are often implicated in cancer and are ideally suited for pharmacological inhibition, the analysis was focused on this class of proteins. Overall, 30 distinct RTKs passed the filtering process during RNA-seq analysis due to their expression level in our XL collection.
Outlier expression analysis identified ten (log2 ratio ≥ 3.5) overexpressed receptor tyrosine kinase genes including ERBB2, AXL, FGFR1, NTRK1, NTRK2, ROR2, RET, EPHA4, EPHB1 and EPHB6 in individual xeno-derived cell lines (Fig.5 ).
Among these, only two identified RTKs were overexpressed in RAS/RAF wildtype cells ("WT-specific" RTKs), namely NTRK1 (TRKA) and ERBB2 (HER2).
Integrated analysis showed that their overexpression is associated to different molecular alterations, namely, gene translocation (NTRK1) or gene amplification (ERBB2) respectively ( Fig. 5 and Supplementary Fig. S8A, S8B and S9).
In the TRKA overexpressed case, we identified a genetic rearrangement involving exon 10 or 11 of LMNA and exon 11 of NTRK1 genes (48, 49) . The two distinct splice variants encoding exons 1-10 or 1-11 of LMNA gene fused to exons 11-16 of NTRK1 gene reported in the donor patient were identified by RNA-seq analysis in the matched xeno cell line ( Supplementary Fig. S9 ).
Remarkably, the pharmacological response of these xeno-cells resembled the one observed in the corresponding PDX upon entrectinib treatment (48) .
In order to validate ERBB2 amplification as an actionable target, we first evaluated biochemical pathway activation. In contrast to CRC0186-XL, CRC0080-XL showed lower level of HER2 protein, but still an active downstream pathway due to the presence of the L866M mutation ( Supplementary Fig. S8C ).
This analysis confirmed that overexpression and constitutive signaling as well as downstream pathway activation of HER2 paralleled the extension of ERBB2 gene amplification.
To validate overexpressed ERBB2 as putative target for pharmacological inhibition (12), we challenged our in vitro models with rational combinations of drugs. We initially tested the effect of drugs (lapatinib and trastuzumab) that have previously shown activity on HER2 positive metastatic CRC patients (12, 50) . While monotherapy showed no or mild effects, both lines (CRC0080-XL and CRC0186-XL) displayed significant sensitivity to the combinatorial treatment ( Fig. 5C ) in short-term proliferation assays. We performed western blot analysis showing that the biological effect of the drugs on ERBB2amplified CRC cell lines is matched by the quenching of HER2 biochemical downstream signals ( Fig. 5D ). Of note, similar results were also obtained in vivo, when the corresponding ERBB2-amplified xenopatients were challenged with the same treatments for 28-35 days (51) (Fig. 5E) , thus confirming the XL as a valuable preclinical model to assess drug response and to dissect biochemical pathway activation.
Combinatorial treatment with lapatinib and trastuzumab of HER2+ patients has been exploited in the recently completed proof-of-concept clinical trial named HERACLES (50) . Our previous work based on liquid biopsy analysis has shown that 32 out of 35 patients treated with anti-HER2 inhibitors relapsed after initial response revealing the presence of molecular mechanisms potentially responsible for resistance (primary or acquired) to HER2 blockade (52) . In particular, either KRAS or BRAF mutated clones were preferentially found in patients who were initially refractory to anti-HER2 treatment (primary resistance), while PIK3CA mutations were detected at progression in patients who had responded to lapatinib+trastuzumab combinatorial treatment and then relapsed (acquired resistance). In order to validate these genetic players as putative drivers of resistance, we transduced HER2+ CRC XL-cells by means of lentiviral vectors and performed pharmacological and biochemical analysis of treated cells. We found that overexpression of mutant alleles of KRAS, BRAF and PIK3CA conferred resistance to combinatorial treatment ( Fig. 6A and Supplementary Fig. S10A ), due to sustained ERK and/or AKT activation ( Fig. 6B and Supplementary Fig.   S10B ).
Discussion
Human cancer cell lines represent a tool extensively exploited in the last half century to study the biology of different tumor types as well as for extensive drug screening efforts. Exceptional efforts such as the generation of the Cancer Cell Line Encyclopedia (7) have been pivotal for unveiling novel genomic correlates of drug sensitivities in 36 tumor types, thus coupling cell line genomic annotation to individual pharmacological profiles.
We have previously described a bowel cancer cell-line collection including It is now evident that CRC is indeed a heterogeneous disease whose development and progression rely on continuous evolution of multiple clones under environmental and pharmacological pressure (54) .For this reason, precision medicine, which is based on the design of personalized treatments, requires a repertoire of preclinical models that mirror the in vivo tumor more closely than conventional cancer cell lines. Derivation of longterm culture directly from tumor samples has proven to be difficult and inefficient, at least in CRC, not only because of contaminations but also due to failure to adhere to the culture dish or loss of proliferative capacity after a few passages (55) . Establishment of short-term tumor cell culture has proven to be successful (56) , but long-term experiments as well as gene editing by lentiviral transduction for experimental needs might not be feasible.
Generation of PDX models has contributed to the identification and validation of biomarkers of response and resistance to current anticancer therapies (17) .
However, they present some important shortcomings such as long time for establishment and expansion, cumbersome manipulation and cost-ineffective experiments, especially if set on a large scale.
Here we present a complementary approach based on PDX-derived cell lines.
We In line with these observations, gene expression profiles of matched XLs and PDX models were highly correlated, confirming the stability of the tumor models upon propagation in vitro. Likewise, the molecular classification of cell lines based on transcriptional traits did reproduce the occurrence observed in the original tumor, and conserved its distinct associations with genetic, molecular and pharmacological associations. Indeed, despite the small size of our dataset, we could confirm the association between CRIS-C assignment and higher probability of response to anti-EGFR treatment, as well as the association between CRIS-A and MSI status.
Of note, comparing the classification of CMS and CRIS in the context of cell models we unveiled correspondence in classification of CMS4 and CRIS-D, likely emerging due to absence of stromal cells in the cancer cells profiles and similarities in intrinsic traits, such as the LGR5 stem-like signature detected in both subtypes (29, 57) .
We next assessed whether these new preclinical models could represent a reliable tool for biomarker validation and pharmacological screening. Another notable advantage provided by this approach is the possibility of generating cell lines with genotypes that are either missing o rare in common commercial repositories (i.e. HER2 amplified or NRAS Q61 mutated cell lines), as well as increasing the number of MSS CRC cell lines, which are typically underrepresented in existing cell line collections (34, 53) . It derives that the more XLs we manage to establish, the more we will have the chance to understand and model the molecular underpinnings of CRC heterogeneity.
In conclusion, we present a novel preclinical platform thatowing to its reliability, large-scale use and proximity to original patient tumorscould offer easier and more rapid access to the dissection of genetic and patientselective therapeutic vulnerabilities, thus leading to the design of novel effective treatment strategies. Figure 6 A B
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